Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Sarepta Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
MiMedx Group Inc June 18, 202590.3%
-
Sarepta Therapeutics Inc. June 5, 202592.8%
-
MiMedx Group Inc June 5, 202496.5%
-
Sarepta Therapeutics Inc. June 8, 202386.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 4, 2026 | Sarepta Therapeutics Inc. | Grant or award | +16,875 | — | — |
| Jan 27, 2026 | Sarepta Therapeutics Inc. | Option exercise | +10,500 | $13.71 | $143,955 |
| Jan 27, 2026 | Sarepta Therapeutics Inc. | Shares withheld for tax | −6,494 | $22.17 | $143,972 |
| Jun 18, 2025 | MiMedx Group Inc | Grant or award | +28,609 | $6.47 | $185,100 |
| Mar 10, 2025 | Sarepta Therapeutics Inc. | Grant or award | +2,383 | — | — |
| Sep 4, 2024 | Sarepta Therapeutics Inc. | Gift | −746 | — | — |
| Jul 3, 2024 | Sarepta Therapeutics Inc. | Option exercise | +15,000 | $13.90 | $208,500 |
| Jun 5, 2024 | MiMedx Group Inc | Grant or award | +23,190 | $7.26 | $168,359 |
| Mar 1, 2024 | Sarepta Therapeutics Inc. | Grant or award | +1,846 | — | — |
| Nov 3, 2023 | Sarepta Therapeutics Inc. | Option exercise | +15,000 | $29.03 | $435,450 |
| Jun 13, 2023 | MiMedx Group Inc | Grant or award | +35,354 | $4.95 | $175,002 |
| Mar 6, 2023 | Sarepta Therapeutics Inc. | Grant or award | +1,523 | — | — |
Questions about M. Kathleen Behrens
What boards is M. Kathleen Behrens on?
M. Kathleen Behrens sits on the boards of MiMedx Group Inc and Sarepta Therapeutics Inc.
How long has M. Kathleen Behrens served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.